BGLA.F BIOGAIA AB B O.N.

Healthcare Pharmaceuticals Frankfurt Exchange
11.52 EUR
Close of Nov 11, 2026
8.51 12.32
Market cap
EUR 1.14B
P/E
31.2x
P/B
10.30x
ROE
32.0%
Dividend yield
1.33%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is BGLA.F undervalued?

Graham number

The Graham number of BIOGAIA AB B O.N. cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

BIOGAIA AB B O.N. fundamental analysis

No fundamental analysis for BIOGAIA AB B O.N. yet.

BIOGAIA AB B O.N. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About BIOGAIA AB B O.N.

BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. I…

Full company profile